Tecfidera Label Change and FDA Drug Safety Communication Regarding PML
The U.S. Food and Drug Administration (FDA) recently announced that it added new information to the label for Tecfidera (dimethyl fumarate) regarding progressive multifocal leukoencephalopathy (PML). The FDA based its decision on a report of a multiple sclerosis (MS) patient who, while being treated with Tecfidera, developed PML then died. The patient was a 54… Continue reading
